BERLIN: German pharmaceutical maker BioNTech, which developed the first widely used coronavirus vaccine with Pfizer, saw its profits surge in the second quarter of 2021.
The Mainz-based company said Monday that it made a net profit of almost 2.8 billion euros (USD 3.3 billion) from April to June.
This boosted first-half net profits to over 3.9 billion euros, compared with a net loss of almost 142 million euros in the first six months of 2020.
The company has said the windfall from its mRNA-based coronavirus vaccine will help it to develop drugs against cancer and other diseases.